phd hematology

Division of Hematology

Soumaya Zlitni, PhD, AACR Award Recipient at the AACR Annual Grants Reception and Dinner. See Bhatt Lab

Kuo Lab Learn more

Artandi Lab Learn more

Dr. stanley schrier's gift fund    .

To learn more about making a gift in Dr. Schrier's memory, click here .   

Dr. Steven Coutre’s Gift Fund

To learn more about making a gift in Dr. Coutre's memory click here .  

Make a Gift to the Division of Hematology

To learn more about how to make a gift to the division, visit here .

Donate Here

We are seeking a Life Science Research Professional 1 position to work in the world-renowned Kuo lab in cancer research.

Reimbursement Forms

Faculty reimbursement form.

Stanford Faculty can submit their expense reimbursement requests via this link: 

Non-Faculty Reimbursement

Hematology Expense Reimbursement Request Form

All other expense reimbursement requests can be submitted by using the following form:

Travel Reimbursement Guidelines

Slides Here

Travel Reimbursement Video

Featured publications.

See Below for other publications

Jason Gotlib, MD

Message from the Division Chief

Welcome to the Stanford Division of Hematology, a dynamic center for basic and translational research, clinical trials, patient care, and teaching. Our physicians, scientists, staff, and trainees collaborate to advance the understanding and treatment of hematologic cancers and non-malignant hematologic disorders, all with the goal of improving outcomes for our patients. In pursuit of this objective, we engage with the broader Stanford community to bring innovation and cutting-edge science to our efforts.

There has never been a more exciting time to be a hematologist! The pace of discovery coupled with rapid translation from laboratory to clinic is improving outcomes for patients. Our Division is proud of its strong roots in basic science and we are committed to bringing novel discoveries and therapies to our patients.

Our physicians have expertise in a broad range of hematologic disorders including acute and chronic leukemias, myeloproliferative neoplasms, myelodysplastic syndromes, multiple myeloma, amyloidosis, thrombotic diseases, coagulation disorders, and general hematology.

The basic and translational research efforts of our Division encompass a broad range of focus areas including stem cell biology, cancer and leukemia stem cells, telomere biology, myeloid malignancies, genomics and single-cell multi-omics, the microbiome, human organoids, vascular biology and the role of thrombin-cleaved osteopontin in coagulation and cancer.

Our passionate and dedicated faculty members have mentored and trained leaders in the field of hematology and are excited to inspire and guide the next generation of leading physicians and research scientists.

We are committed to diversity, equity and inclusion within our Division and in academic medicine more broadly.

We invite you to learn more about us through our website.

Congratulations Dr. Rondeep Brar Medical Director for Cancer DSL and SCI’s Associate Director for Clinical Care

Rondeep Brar, MD, Named Medical Director for Cancer DSL & SCI’s Assoc. Director for Clinical Care

Dear Colleagues,

We are delighted to announce that Rondeep (Roni) Brar, MD, clinical associate professor of Medicine, has been appointed Stanford Health Care’s Medical Director for the Cancer Destination Service Line (DSL) and Stanford Cancer Institute’s Associate Director for Clinical Care. He began in these dual roles on Monday, February 6.

Over the last decade, Dr. Brar has shown tremendous vision in re-imagining and elevating our health system’s inpatient cancer care services and ambulatory hematology practice. This includes engaging with and leading teams to redesign the Advanced Practice Provider (APP) system, improve inpatient documentation, grow patient volumes, and increase and diversify clinical trial enrollments.

These successes are a testament to Dr. Brar’s strong leadership, expansive expertise, cutting-edge clinical research, and compassionate care. They also reflect his vast institutional knowledge and the strong collegial relationships he has formed across Stanford Medicine. 

After receiving his MD from UCLA in 2007, Dr. Brar completed his internal medicine residency at Stanford in 2010, and his fellowships in hematology and oncology at Stanford in 2012. Dr. Brar was then recruited as a Clinical Assistant Professor in the Department of Medicine, Division of Hematology in 2012. He was subsequently promoted to Clinical Associate Professor in 2018.

Since August 2021, alongside Heather Wakelee, MD, Dr. Brar has served as the Interim Medical Co-Director of the Cancer DSL. During this time, Drs. Brar and Wakelee have re-aligned the structure and leadership of the Cancer Care Programs, reconfigured the leadership cabinet to represent a broader constituent group, and engaged in strategic planning for our joint ventures and future campus expansion. Dr. Brar will work closely with Drs. Artandi and Seshadri as well as Maria Gonzalez, Executive Director of the Cancer DSL, to shape and implement the future of the Cancer DSL.

Dr. Wakelee will continue to provide interim support through March 2023 as Dr. Brar transitions some of his clinical operations. We want to thank Dr. Wakelee for her dedication and stellar leadership as she continues her exemplary service as the Division Chief of Medical Oncology and Deputy Director of SCI and for her extensive work in enhancing cancer clinical trials.

We also want to express our gratitude to our search committee and the stakeholders across Stanford Medicine who helped facilitate this important search.

We are excited to have Dr. Brar serve in these leadership roles and look forward to his contributions. Please join us in congratulating Dr. Brar on this well-deserved recognition.

Sincerely,  Steve, Sri, and Niraj

Team science is a key priority for the Department of Medicine  

Dr. Majeti is highlighted as our Division Team Science Representative 

Julia Ranshoff’s research has been featured in

Stanford medicine news center.

National Comprehensive Cancer Network Spotlight on NCCN leaders

NCCN Guidelines Panel Members

Congratulations to Dr. Mannis!

Congradulations Dr. Sydney Lu

The American Society of Hematology (ASH)  selected Dr. Sidney Lu for the 2023 ASH Junior Faculty Scholar Award in basic/translational research .

Dr. Lu is part of this prestigious ASH award program.

Congratulations Soumaya Zlitni on being recognized as the JEDI Champion!

Stanford Postdoc JEDI Champion Awards recognize current Stanford University postdoctoral scholars who have championed initiatives, activities, and efforts that advance justice, equity, diversity, and inclusion at Stanford and beyond.

Dr. William Shomali featured in the 2022 Annual Report 

William Shomali, MD Hematoligist shares his journey. 

Medicine Annual Report 2022

Dr. Jason Gotlib featured in the 2022 Annual report 

Dr. Jason Gotlib, MD, MS Clinical Trialist shares his passion for photography and clinical studies in Hematology. 

Dr. May Chien featured in the 2022 Annual Report 

Dr. May Chien, MD shares on becoming a Classical Hematologist

Bhuvana Ramachandran

Bhuvana Ramachandran, Hematology Administrator shares what it take to run a Division.

The faculty retreat was held on Aug 20, 2022 to discuss various strategic initiatives. We also welcomed our Interim Chief, Dr. Beverly Mitchell, who will be leading the division from Sep 1, 2022. Thank you all for your presentations, discussions, and ideas that we plan to implement in the future!

Congradulations Dr. Mannis

Dr. Gabe Mannis is the recipient of the Department of Medicine Teaching Award for 2021.  He was honored in an award ceremony on Nov 2, 2022 at the LKSC Berg Hall.

Halloween Fun at MED8

The Med 8 Team celebrated Halloween in true Hematology fashion, with “costumes” of various blood cells - Neutrophil, B cell, Eosinophil, Natural Killer Cell, and CD4 T cell.  Thanks to Mike Glover who organized this fun costume!

Welcome New Faculty

Congratulations to the hematology/oncology fellowship leadership team and admin team.

The Hematology/Oncology fellowship has gained dual ACGME accreditation under the leadership of Dr. Tamara Dunn (pictured left) and Dr. Gregory Heestand (Pictured below).

The division celebrates this remarkable success and recognizes the hard work of the faculty and administrative leadership. Administrative efforts were led by Program Manager, Michelle Gomez, and Lead Program Coordinator, Maria Carrasco.

Recent Appointments

Dr. Michaela Liedtke has been appointed as our Clinical Chief for Hematology.

Read the full press release here

SHC once again named on U.S. News & World Report's "Best Hospitals" Honor Roll

Stanford Cancer Care jumped from 21st to 12th!

Stanford Health Care (SHC) has once more been named one of the country's top hospitals. Notably, Stanford Health Care achieved national acclaim in Cancer among other areas in the domains of safety, quality of care, patient experience, and patient outcomes. Stanford's Cancer Care had a remarkable jump from 21st to 12th!

Overall, Stanford Hospital's national ranking rose to 12th, ranking 4th in California and 1st in the San Jose metropolitan area. Special thanks to our Hematology and Oncology Physicians and SHC for this remarkable performance!

Resident Research Retreat April 2021 with Dr. Chien and Dr. Mannis

Hematology Newsletters

Fall 2024 Hematology Newsletter

Newsletter Archive

Subscribe to our newsletter by emailing  [email protected]

Mark Your Calendars!

ASH is returning to San Diego for the 66th ASH Annual Meeting and Exposition from December 7-10, 2024. Register Here Registration and housing for ASH members opens July 17, 2024, at 11:00 a.m. Eastern time.

Congratulations

Dr. sydney x. lu for being the recipient of the, young physician-scientist awards, 2024.

Congratulations to Dr. Iberri on his Outstanding Lecture Award!

David Iberri, MD, Clinical Assistant Professor in Hematology, Department of Medicine, received the Outstanding Lecture Award for his lecture on plasma-cell dyscrasias in the Science of Medicine course. This award recognizes a faculty member who demonstrates exceptional skill in developing and delivering a lecture or presentation. The award was presented at the 2023 Stanford Medical Education Awards Ceremony on June 1, 2023.

Dr. Ilana Yurkiewicz Fragmented: A Doctor’s Quest to Piece

Together American Health Care

The Medicine & the Muse Program recently hosted a book reading and discussion to celebrate the launch of Fragmented: A Doctor's Quest Piece Together American Health Care by: Ilana Yurkiewicz, former Hematology fellow and VA Faculty. 

Featured in Photo: Dr. Michaela Liedtke, Dr. Ilana Yurkiewicz, Dr. Caroline Berube

Faculty Highlights

Dr. Tamara Dunn was featured on the CBS morning news on Friday, January 22, 2021 as she was speaking on the importance of getting the COVID-19 vaccine.

Immunotherapy Gives Hope to Multiple Myeloma Patients - Dr. Michaela Liedtke is featured.

Dr. Tamara Dunn , selection to the ASH Medical Educator Institute.

Dr. Beth Martin , Henry J. Kaiser Family Foundation Award for Excellence in Pre-Clinical Teaching

Dr. Jason Gotlib , University of Vienna Researcher of the Year, ECNM Medal and Trophy, 2019.

Dr. David Iberri Division Teaching Award, 2019.

Drs. Hall and Zehnder, March 2019 American Journal of Clinical Pathology

Drs. Yurkiewicz, Liedtke and Dunn, October 2018 Journal of Young Adolescent and Young Adult Oncology

Yurkiewicz , Simon, Liedtke , Dahl and Dunn authors Effect of Fitbit and iPad Wearable Technology in Health-Related Quality of Life in Adolescent and Young Adult Cancer Patients

Drs. Baird and Gotlib, 2018 Hematologic Malignancy Reports

John Baird , MD, Jason Gotlib , MD, MS on recent developments in the treatment of advanced systemic mastocytosis (advSM) with inhibitors of the KIT receptor tyrosine kinase.

Haematology MPhil/PhD

London, Bloomsbury

This is the programme information for 2025 entry

If you require details of the previous year's programme, Haematology MPhil/PhD (2024), click here

When you study a haematology research degree at the UCL Cancer Institute, you join a supportive and intellectually rigorous environment to develop your research skills, subject knowledge, and critical review abilities. Our excellent facilities, supervision and training opportunities prepare you for careers in academia, industry, business, biomedicine, and healthcare.

UK tuition fees (2025/26)

Overseas tuition fees (2025/26), programme starts, applications accepted.

• Entry requirements

A minimum of an upper second-class UK Bachelor’s degree in a relevant discipline or an overseas qualification of an equivalent standard.

The English language level for this programme is: Level 3

UCL Pre-Master's and Pre-sessional English courses are for international students who are aiming to study for a postgraduate degree at UCL. The courses will develop your academic English and academic skills required to succeed at postgraduate level.

Further information can be found on our English language requirements page.

Equivalent qualifications

Country-specific information, including details of when UCL representatives are visiting your part of the world, can be obtained from the International Students website .

International applicants can find out the equivalent qualification for their country by selecting from the list below. Please note that the equivalency will correspond to the broad UK degree classification stated on this page (e.g. upper second-class). Where a specific overall percentage is required in the UK qualification, the international equivalency will be higher than that stated below. Please contact Graduate Admissions should you require further advice.

About this degree

Haematology is one of five research departments within the Cancer Institute. It covers areas such as leukaemia biology, stem cell transplantation, transplantation immunology, tumour Immunology, cellular and gene therapy, multiple myeloma, and tumour immunodynamics.

You will develop your research hypothesis with your supervisors, and undertake novel laboratory, bioinformatic or clinical research as part of their research team. You will be supported by a supervisory team including your principal supervisor, and a thesis committee which comprises a secondary supervisor and one to three committee members.

Knowledge and skills development is a core priority of our programme. As well as UCL's Doctoral Skills Programme, the Cancer Institute runs a compulsory first-year training programme that will improve your research skills and provide networking opportunities.

This Haematology PhD programme is based in London and is available on a full-time or part-time basis.

Who this course is for

We welcome high achieving students who want to join a world-class centre to do haematology research. Students come from all over the world and from a wide range of backgrounds, including clinicians, scientists and anyone interested in haematology.

What this course will give you

• A unique opportunity to work in a collaborative research environment that spans basic research, translational medicine, and clinical applications.
• Close links with associated clinical trials facilities, experimental cancer medicine centre, biobanking facilities and associated partners and hospitals in London such as the Royal Free Hospital, UCLH, and Cancer Research UK and the Crick Institute.
• Skills development, including bench and technical skills, critical evaluation of scientific literature, experimental planning and design, interpretation of data results, presentation/public speaking skills, time and project management, working within a team, working independently, and writing for various audiences.

The foundation of your career

Our excellent facilities, supervision and training opportunities prepare you for future careers in academia, industry, business, biomedicine, and healthcare.

According to the HESA Graduate Outcomes survey (2018-2022), around 95% of our PhD graduates in Haematology were in work (90%) or further study (5%), with the vast majority in highly skilled roles.

Employability

According to the HESA survey, our Cancer PhD graduates specialising in Haematology have gone onto a range of destinations and employers. These include:

• Overseas hospitals (Amsterdam UMC, King Faisal Specialist Hospital, St Jude Children’s Research Hospital)
• Cancer research organisations (Francis Crick Institute, King Abdullah International Medical Research Centre)
• CAR-T cell therapy specialists (Autolus)
• Universities (UCL).

Most are employed as biochemists and biomedical scientists, researchers, or as specialist medical practitioners. Others are GPs or science writers / translators.

The programme is designed to give you networking opportunities throughout your period of study.

These include weekly internal divisional seminars, a weekly external speaker seminar and reception, and student poster sessions. You will also attend the Annual Cancer Institute Conference, as well as national and international research conferences, and academic careers days. 

On graduating, you will be able to join the Institute’s alumni network on LinkedIn.

Teaching and learning

Most of your research will be carried out independently. There will also be a series of training requirements that you will need to complete in the early stages of the programme.

All research students attend a compulsory training programme on lab skills during the first year. This covers:

• Human Tissue Act and the Biobank
• Tissue Preparation and Staining
• Basics of Proteomics
• Principles of Good Clinical Lab Practice
• Clinical Trial Design and Regulation
• In vivo Study Design and Regulation
• Preclinical Radiotherapy
• Single Cell Analysis.

All students are part of UCL’s doctoral school research training programme and collect 20 training points per year.

Your first milestone will be to upgrade from MPhil to the PhD degree. For this, you will submit and present a report. In your final year, you submit a thesis covering your research and discuss this at a formal interview known as a viva examination.

Most of your time will be spent conducting independent research, alongside regular meetings with your supervisory team and completing your training requirements. We also encourage you to attend relevant research events at UCL and elsewhere.

Contact hours and hours of self-study are agreed between the student and the supervisor at the beginning of their research degree and should be reviewed on a regular basis. Full-time postgraduate research students are expected to work at least 36.5 hours per week on their project.

Contact time tends to be on-site. However, by agreement of the supervisors, remote working might be possible at times, depending upon the nature and stage of the project.

PGR students can access UCL facilities ‘out of hours’ including weekends and holidays during their period of registration. Students have research meetings with their supervisors at least once per month and attend weekly lab meetings when appropriate.

Research areas and structure

• Acute myeloid Leukaemia and multiple myeloma
• Cellular and gene therapy
• Dendritic cell immunotherapy
• Immune regulation and tumour immunotherapy
• Molecular cytogenetics
• Stem cell transplantation and cellular immunotherapy
• Transplantation immunology
• Translational immunotherapy

Research environment

UCL is a top-rated university in the UK for research strength in the Research Excellence Framework (REF 2021). Our scientists have an international reputation for leading basic, translational, and clinical cancer research and the Cancer Institute is uniquely positioned to leverage the multidisciplinary nature of UCL by engaging a range of disciplines to transform cancer research.

You will join a community of over 300 research scientists and 120 research students within the Cancer Institute. Our combination of fundamental cancer research, clinical links with UCLH, and the Royal Free Hospitals, and collaborative links with the Crick Institute and Cancer Research UK, make the Cancer Institute an exciting environment for basic and translational research into cancer.

The Department of Haematology has a range of research groups, including:

• Dendritic Cell Immunotherapy
• Leukaemia Biology
• Signal Transduction and Drug Resistance in Leuk...
• Stem Cell Transplantation & Cellular Immunotherapy
• Translational Immunotherapy
• Transplantation Immunology
• Tumour Immunology, Cellular and Gene Therapy
• Biology of Adult Lymphoblastic Leukaemia and Oncolytic Virus Therapy
• Immune Regulation and Tumour Immunotherapy Lab
• Multiple Myeloma Lab
• Tumour Immunodynamics Research Group.

We encourage you to become part of the community and to present and discuss your work at research team meetings, Institute Research in Progress talks, the annual Cancer Institute conference and Research Student poster day. You will also be encouraged to present at relevant international conferences and, where appropriate, to contribute towards scientific publications in your field.

The duration of a full-time research degree is usually three to four years. You register initially for the MPhil degree.

Within three months of joining the programme, you will be expected to agree the basic structure of your research project with your supervisor, along with the appropriate research methods and a realistic plan of your work. You will produce and submit a detailed outline of your proposed research to your supervisor and thesis committee for comments and feedback.

You will then undertake this project as part of your supervisor’s research team. Training workshops at the Cancer Institute will run from January to October.

In your second year, you continue to explore your research hypothesis and to collect and analyse novel data. You will also be expected to upgrade from MPhil to PhD.

To complete your upgrade, you submit a report summarising your research to date, and present and answer questions about this work at a viva voce examination. You also present your research to the department at a Research in Progress seminar.

In your third year, you complete your data collection and analysis, and prepare your thesis. You will also be encouraged to present your findings at an international conference or annual Cancer Institute conference.

Following the third year, you may be eligible for a year of 'completing research status' to complete your thesis and to take your viva examination.

The duration of a part-time research degree is usually five years. You register initially for the MPhil degree.

Within five months of joining the programme, you are expected to agree the basic structure of your research project with your supervisor, along with an appropriate research method and a realistic plan of your work. You will produce and submit a detailed outline of your proposed research to your supervisor and thesis committee for comments and feedback.

In your second and third years (18-36 months), you will continue to explore your research hypothesis and collect and analyse novel data. You will also be expected to upgrade from an MPhil to a PhD.

To complete your upgrade, you submit a report summarising your research to date, and then present and answer questions about this work at a viva voce examination. You also present your research to the department at a Research in Progress seminar.

In your fourth and fifth years, you complete your data collection and analysis, and prepare your thesis. You will also be encouraged to present your findings at an international conference or annual Cancer Institute conference.

Following the fifth year, you may be eligible to transfer to 'completing research status' for two years to complete your thesis writing and to undertake your viva examination.

Accessibility

Details of the accessibility of UCL buildings can be obtained from AccessAble . Further information can also be obtained from the UCL Student Support and Wellbeing Services team .

Fees and funding

Fees for this course.

The tuition fees shown are for the year indicated above. Fees for subsequent years may increase or otherwise vary. Where the programme is offered on a flexible/modular basis, fees are charged pro-rata to the appropriate full-time Master's fee taken in an academic session. Further information on fee status, fee increases and the fee schedule can be viewed on the UCL Students website: ucl.ac.uk/students/fees .

Additional costs

Students receive a free printing allowance each year and pay for any additional printing ( see details ). You may also face additional expenses if you attend conferences. The cost depends on the location, exchange rates, and the price of travel and accommodation, but this may be between £200 and £500 per event, based on typical events / destinations attended by recent students. The Cancer Institute provides two competitive travel scholarships each year to support research students attending training workshops or international conferences.

If you are doing a wet lab project, there may be an Additional Fee Element (AFE, also known as bench fees). This is an additional annual cost related to consumables, equipment or materials based on your individual project. This is payable by your sponsor, or yourself, if self-funding. These additional costs depend on the project and will be the same for home and overseas students.

The Cancer Institute provides some competitive travel scholarships to support research students attending training workshops or international conferences.

UCL’s main teaching locations are in zones 1 (Bloomsbury) and zones 2/3 (UCL East). The cost of a monthly 18+ Oyster travel card for zones 1-2 is £114.50. This price was published by TfL in 2024. For more information on additional costs for prospective students and the cost of living in London, please view our estimated cost of essential expenditure at UCL's cost of living guide .

Funding your studies

Annual CRUK funded clinical fellowships and non-clinical PhD studentships are available. Please check the Cancer Institute website for details. Other funded studentships will also be advertised on the Institute website as they become available. Some of our students seek funding from their home country or cancer charities.

For a comprehensive list of the funding opportunities available at UCL, including funding relevant to your nationality, please visit the Scholarships and Funding website .

Your first steps are to find a supervisor and funding before applying. You should check both the UCL and the Cancer Institute's studentships to apply for specific projects with grants. You can also reach out directly to any potential supervisor, particularly if you have funding in place from another source. You can identify Principal Investigators via the Cancer Institute website and research them individually. If you need help, please see applying for graduate research study or contact the Admissions Tutor on [email protected].

You can apply at any time. However, there are three entry points over the year. Deadlines and start dates are usually dictated by funding arrangements and supervisor availability, so discuss this with your supervisors.

Please note that you may submit applications for a maximum of two graduate programmes (or one application for the Law LLM) in any application cycle.

Choose your programme

Please read the Application Guidance before proceeding with your application.

Year of entry: 2025-2026

Year of entry: 2024-2025, got questions get in touch.

Cancer Institute

[email protected]

UCL is regulated by the Office for Students .

Prospective Students Graduate

• Graduate degrees
• Taught degrees
• Taught Degrees
• Applying for Graduate Taught Study at UCL
• Research degrees
• Research Degrees
• Funded Research Opportunities
• Doctoral School
• Funded Doctoral Training Programmes
• Applying for Graduate Research Study at UCL
• Teacher training
• Teacher Training
• Early Years PGCE courses
• Primary PGCE courses
• Secondary PGCE courses
• Further Education PGCE programme
• How to apply
• The IOE approach
• Teacher training in the heart of London
• Why choose UCL?
• Entrepreneurship
• Inspiring facilities and resources
• Careers and employability
• Your global alumni community
• Your wellbeing
• Postgraduate Students' Association
• Your life in London
• Accommodation
• Funding your Master's

Internal Medicine

• Division of Hematology & Hematologic Malignancies

PhD Graduate Programs

Many faculty members in the hematology division are training faculty in two interdisciplinary PhD graduate programs. These programs in molecular biology and biological chemistry provide a cross-disciplinary, collaborative training environment that enables students to experience a wide-ranging selection of research opportunities representing 11 departments at the University of Utah. Each program is distinct in its core curriculum and requirements.

The programs allow students to experience a broad scientific education, yet tailor their training to their specific interests. Students will participate in cutting-edge research mentored by world-class scientists. In addition, the programs provide the thorough training necessary to become a creative and analytical thinker essential of a successful career in science. 

Read a full description of the programs .

Training opportunities exist in these research programs. To get more information on research opportunities, you can either contact a specific faculty member or contact us .

• ASH Foundation
• Cookie Settings
• Log in or create an account
• Publications
• Diversity Equity and Inclusion
• Global Initiatives
• American Society of Hematology

Resources for PhDs

• Agenda for Nematology Research
• Precision Medicine
• Genome Editing and Gene Therapy
• Immunologic Treatment
• Research Support and Funding

ASH is committed to supporting the participation of basic science-trained investigators in hematologic research and in promoting their participation in the Society’s activities. Below, please find resources, awards, and opportunities for committee and leadership positions for basic scientists involved in hematology-focused research.

ASH Academy on Demand

Nominations for Committee Positions

ASH seeks a balanced committee membership for the Society’s scientific and standing committees

The Society encourages members to self-nominate or recommend a colleague for one or more of the various leadership and committee service roles. All nominations must be submitted online using the ASH nominations submission system.

Grants Clearinghouse

Hematology grant opportunities provided by the ASH Trainee Council to aid trainees in their search for grant information

A database of hematology grant opportunities provided as a service by the ASH Trainee Council. The database lists opportunities offered by organizations external to ASH.

Trainee-News

The ASH Trainee Council is dedicated to increasing the involvement of trainees in basic and clinical hematology research

The American Society of Hematology solicits trainee input on issues related to training and education.

ASH Awards for PhDS

A variety of early-career and early-to-mid career funding opportunities for PhDs offered through ASH award programs

ASH Minority Hematology Graduate Award This award provides funding for students from historically underrepresented minority groups to pursue a career in academic hematology. It is open to doctoral students in their first, second, or third year of graduate school at the time of application.

ASH Abstract Achievement Awards and Outstanding Abstract achievement Awards These $500 merit-based awards (formerly Travel Awards) are provided to trainees with high-scoring annual meeting abstracts of which they are the first or senior author and presenter.

ASH-EHA Translation Research Training in Hematology This training and mentoring program, which kicks off with a week-long course in Europe, helps junior researchers build successful careers in hematologic translational research.

ASH Latin American Training Program This program helps build hematology capacity in Latin America by providing funding for hematologists or hematology-related health care professionals to receive 12 weeks of training on a specific priority area for the region.

ASH Minority Hematology Fellow Award This award encourages early-career MD/DO, PhD, and MD/DO-PhD researchers from historically unrepresented minority groups to pursue a career in academic hematology.

ASH Scholar Award This award provides fellows and junior faculty with partial salary or other research support during that critical period required for completion of training and achievement of status as an independent investigator.

ASH Bridge Grant This award provides funding for investigators who submitted a hematology-related NIH R01 grant in the past 18 months and whose proposals were scored but denied funding.

ASH Global Research Award This award was designed to support future international scientific leaders, increase hematology capacity, and nurture global collaboration.

Job Seekers Take the next step on your career path - find the job that fits your skills and goals. Sign in or create a free account to post your resume and save job listings of interest.

Employers Connect to thousands of qualified hematology and hematology-oncology professionals through the ASH Job Center, the top online search result for hematology jobs. Sign in to explore options to post your listing.

FAQs Review frequently asked questions about how the ASH Job Center can help you as a job seeker or an employeer.

Research and Resources

Journal Club The ASH Journal Club discusses seminal papers in hematology published in Blood or Blood Advances , and features a manuscript author  as part of the engagement.

Agenda for Hematology Research The ASH Agenda for Hematology Research serves as a roadmap for the prioritization of research support across the hematology community, including recommendations for dedicated resources from funding agencies and foundations that will equip researchers today and in the future to make truly practice-changing discoveries.

COVID-19 Research Agenda for Hematology Developed in response to the emergence of hematologic complications from COVID-19 infection, this agenda addresses fundamental questions of critical importance to researchers, physicians, and patients.

Spread the Word

Social Media Toolkit Connect with others in the PhD community and spread awareness of ASH resources for PhDs.

Related Content